Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor class drugs

12 results

  • abacavir and lamivudine

    (Abacavir and Lamivudine)
    Laurus Labs Limited
    Abacavir and lamivudine tablets are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection when used in combination with other antiretroviral agents.
    Medication Details
    Drug Interactions

  • complera

    (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)
    Gilead Sciences, Inc.
    COMPLERA® is indicated for treating HIV-1 in adults and children (≥35 kg) as initial therapy for those with no treatment history and HIV-1 RNA ≤100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients. Limitations include risk of virologic failure in those with higher baseline HIV-1 RNA.
    Medication Details
    Drug Interactions

  • delstrigo

    (doravirine, lamivudine, and tenofovir disoproxil fumarate)
    Merck Sharp & Dohme LLC
    DELSTRIGO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg, either as a complete regimen for those with no prior antiretroviral treatment or to replace the current regimen in patients who are virologically suppressed with no history of treatment failure.
    Medication Details
    Drug Interactions

  • descovy

    (emtricitabine and tenofovir alafenamide)
    Gilead Sciences, Inc.
    DESCOVY is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥35 kg) in combination with other antiretroviral agents. It is also approved for HIV-1 pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents (≥35 kg), excluding those at risk from receptive vaginal sex.
    Medication Details
    Drug Interactions

  • dovato

    (dolutegravir sodium and lamivudine)
    ViiV Healthcare Company
    DOVATO is indicated for the treatment of HIV-1 infection in adults and adolescents (aged 12 and older, weighing at least 25 kg) either as a complete regimen for those with no prior treatment history or to replace the current regimen in virologically suppressed patients without resistance concerns.
    Medication Details
    Drug Interactions

  • genvoya

    (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)
    Gilead Sciences, Inc.
    GENVOYA is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥25 kg) with no prior antiretroviral treatment history or to replace an existing regimen in virologically-suppressed patients on a stable regimen for at least six months without treatment failures or resistance.
    Medication Details
    Drug Interactions

  • lamivudine

    (lamivudine oral)
    Chartwell RX, LLC
    Lamivudine oral solution is indicated in combination with other antiretroviral agents for treating HIV-1 infection. It is not intended for use in hepatitis B virus (HBV) treatment.
    Medication Details
    Drug Interactions

  • odefsey

    (emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide)
    Gilead Sciences, Inc.
    ODEFSEY is indicated for the treatment of HIV-1 infection in patients weighing at least 25 kg, either as initial therapy for those with no prior treatment history and HIV-1 RNA ≤ 100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients.
    Medication Details
    Drug Interactions

  • stribild

    (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate)
    Gilead Sciences, Inc.
    STRIBILD® is indicated for treating HIV-1 in adults and pediatric patients aged 12 and older (weighing at least 35 kg) without prior antiretroviral treatment or to replace a stable regimen in those virologically suppressed for at least 6 months, without resistance to its components.
    Medication Details
    Drug Interactions